Efficacy of MF/IND/GLY on lung function and exacerbations in pts with inadequately controlled asthma on medium-dose ICS/LABA (GINA step 4): Results from IRIDIUM

05 May 2022
Respiratory conditions
  • Asthma
Type of resource
Malaga 2022
Huib Kerstjens, Department of Pulmonology, University of Groningen, University Medical Center Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, Netherlands
Clinical Research Results Abstract IntroductionGlobal Initiative for Asthma (GINA) 2020 recommends medium-dose inhaled corticosteroids/long-acting β2-agonist (ICS/LABA) as preferred controller for patients in step 4 therapy. This post hoc analysis from IRIDIUM study evaluated efficacy of once-daily medium- (80/150/50 μg) and high-dose (160/150/50 μg) mometasone/indacaterol/glycopyrronium (MF/IND/GLY) vs twice-daily high-dose fluticasone/salmeterol (FLU/SAL; 500/50 μg) in patients with inadequately controlled asthma (asthma control questionnaire [ACQ]-7 ≥1.5) with medium-dose ICS/LABA therapy prior to enrolment.MethodsIRIDIUM (NCT02571777) was 52-week, randomised, double-blind, parallel-group study in patients with symptomatic asthma (ACQ-7 ≥1.5), ≥1 exacerbation in previous year and predicted forced expiratory volume in one second (FEV1) <80%. Trough FEV1 at Week 26 and annualised rate of exacerbations over 52 weeks were assessed.ResultsIn patients with inadequately controlled asthma with medium-dose ICS/LABA (62.4% at baseline), medium- and high-dose MF/IND/GLY showed greater improvements in trough FEV1 and a greater reduction in exacerbation rate versus high-dose FLU/SAL (Table).ConclusionsIn patients with inadequately controlled asthma with medium-dose ICS/LABA, greater lung function improvement and exacerbation reduction were observed with both doses of MF/IND/GLY versus high-dose FLU/SAL. These results suggest use of MF/IND/GLY as step-up therapy from medium-dose ICS/LABA provides benefit beyond increasing ICS dose. Research Idea Abstract Service Development & Evaluation Abstract Declaration of Interest Huib Kerstjens: Reports grants and fees for consultancy or advisory board participation from Novartis, during the conduct of the study; and grants and fees for consultancy or advisory board participation from GlaxoSmithKline and Boehringer Ingelheim, and a grant from Chiesi, outside of the submitted work. All were paid to his institution. Karen Mezzi: Employee of Novartis Pharma. Funding: The study was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.Trial registration: This study is registered with ClinicalTrials.gov, NCT02571777. References and Clinical Trial Registry Information